10-QPeriod: Q2 FY2001

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Apr 1, 2001

Filed May 14, 2001For Securities:JNJ

Summary

Johnson & Johnson (JNJ) reported strong financial results for the first quarter ending April 1, 2001. The company demonstrated robust sales growth across its key segments, with total sales increasing by 6.5% year-over-year to $7.79 billion. This growth was driven by healthy performance in both domestic and international markets, despite a negative impact from foreign currency exchange rates. Net earnings also saw a significant increase of 14.2%, reaching $1.50 billion, translating to diluted earnings per share of $1.06, up from $0.93 in the prior year's comparable quarter. Key drivers of this performance include strong sales in the Pharmaceutical segment, notably from products like PROCRIT/EPREX and RISPERDAL, and continued momentum in the Medical Devices and Diagnostics segment, buoyed by coronary stents and orthopaedic products. The company also made strategic acquisitions, including BabyCenter, Inc., and announced a significant merger with ALZA Corporation, indicating a focus on expanding its product portfolio and technological capabilities. The company also strengthened its balance sheet by reducing debt and increasing its cash position.

Key Highlights

  • 1Total sales increased by 6.5% to $7.79 billion for the quarter, with operational sales growth of 10.1% excluding currency impacts.
  • 2Net earnings rose by 14.2% to $1.50 billion, with diluted EPS growing to $1.06 from $0.93 in the prior year.
  • 3Pharmaceutical sales grew 7.2% to $3.3 billion, driven by key products like PROCRIT/EPREX and RISPERDAL.
  • 4Medical Devices and Diagnostics segment sales increased by 8.8% to $2.7 billion, fueled by coronary stents and orthopaedic products.
  • 5Acquisition of BabyCenter, Inc. completed and merger agreement with ALZA Corporation announced, signifying strategic expansion.
  • 6Total debt as a percentage of total capital decreased to 10.9% from 15.7% at the end of the previous year, indicating improved financial leverage.
  • 7Quarterly dividend per share was increased by 12.5% to $0.36 (pre-split basis).

Frequently Asked Questions

Johnson & Johnson reported a strong first quarter in 2001. Total sales increased by 6.5% to $7.79 billion, and net earnings grew by 14.2% to $1.50 billion. Diluted earnings per share were $1.06, up from $0.93 in the same period last year.

Sales growth was driven by strong performance across all segments. The Pharmaceutical segment saw a 7.2% increase, led by products like PROCRIT/EPREX and RISPERDAL. The Medical Devices and Diagnostics segment grew 8.8%, supported by coronary stents and orthopaedic products. The Consumer segment also saw growth, particularly in skin care.

The company completed the acquisition of BabyCenter, Inc. and announced a merger agreement with ALZA Corporation, a drug delivery technology company. Additionally, they completed the merger with Heartport, Inc., a pioneer in less invasive cardiac surgery products. These moves indicate a focus on expanding the company's reach and capabilities.

Total borrowings decreased significantly, and total debt as a percentage of total capital fell from 15.7% to 10.9%. Cash and cash equivalents, along with marketable securities, increased, leading to a stronger net cash position.